A covalent inhibitor targeting Cys16 on RhoA in colorectal cancer
8.0
来源：
Cell
关键字：
neural coding
发布时间：
2025-09-06 03:32
摘要：
CL16 is a novel covalent inhibitor specifically targeting Cys16 on RhoA, a key player in colorectal cancer (CRC) progression. This compound has shown significant anticancer and anti-metastatic effects in various CRC models, including in vivo studies, with minimal toxicity. The research highlights the potential of CL16 as a therapeutic agent, establishing RhoA Cys16 as a targetable hotspot for CRC treatment, paving the way for future clinical applications.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
1.0分+1.0分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
CL16 demonstrates antitumor effects in mouse CRC models with no observable toxicity.
Covalent targeting of Cys16 on RhoA offers a promising strategy for CRC treatment.
CL16 inhibits RhoA activity and mediates anticancer properties in CRC primarily through covalent targeting.
真实性检查
否
AI评分总结
CL16 is a novel covalent inhibitor specifically targeting Cys16 on RhoA, a key player in colorectal cancer (CRC) progression. This compound has shown significant anticancer and anti-metastatic effects in various CRC models, including in vivo studies, with minimal toxicity. The research highlights the potential of CL16 as a therapeutic agent, establishing RhoA Cys16 as a targetable hotspot for CRC treatment, paving the way for future clinical applications.